Table 3.

Multivariate analysis results showing that immunotherapy timing remained significant when accounting for age, sex, type of cancer (lung vs. other), and type of radiation treatment.

Multivariate Analysis	p-value
Immunotherapy Timing (Before vs. During/After)	0.0
Age > or <62 years	0.76
Gender	0.53
Lung Cancer vs. Non lung cancer	0.73
SBRT vs. SRS	0.20

SBRT, Stereotactic Body Radiotherapy; SRS, Stereotactic Radiosurgery.